Polycythemia VeraNCT07362225
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
An observational study of Polycythemia Vera and ET (Essential Thrombocythemia), run by MPN Research Foundation at 2 sites in United States.
Trial summary
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), pre-fibrotic primary myelofibrosis… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV)
- How many people
- 5,000 participants
- Where
- 2 sitesUnited States
- Study dates
- 26 Sep 2025to 8 Sep 2035
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults (18 years and older) diagnosed with a myeloproliferative neoplasm (MPN), including polycythemia vera, essential thrombocythemia, primary myelofibrosis, secondary myelofibrosis, pre-fibrotic primary myelofibrosis, MPN-unclassifiable, MPN-accelerated phase, or MPN-blast phase, post-MPN AML, or MDS/MPN overlap syndrome (including patients originally diagnosed with one of these conditions but who have received one or more SCTs or BMTs) residing in the United States. Participants are enrolled exclusively through direct-to-patient outreach using online recruitment, social media, digital advertising, and patient advocacy networks. All participants must provide electronic informed consent, have accessible electronic health record (EHR) data, and be willing to complete digital patient-reported outcome surveys. The study aims to capture a diverse national cohort for real-world, longitudinal research on disease progression, treatment patterns, and outcomes .
Who may be able to join
- Adults aged 18 years or older at the time of enrollment.
- Confirmed diagnosis of a myeloproliferative neoplasm (MPN), including one or more of the following subtypes, according to WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplants (SCTs) or bone marrow transplants (BMTs):
- Polycythemia vera (PV)
- Essential thrombocythemia (ET)
- Primary myelofibrosis (PMF)
- Secondary myelofibrosis (post-ET or post-PV MF)
Show all 16Show fewer
- Pre-fibrotic primary myelofibrosis (pre-PMF)
- Myeloproliferative neoplasm-unclassifiable (MPN-U)
- Myeloproliferative neoplasm, accelerated phase (MPN-AP)
- Myeloproliferative neoplasm, blast phase (MPN-BP)
- Post-MPN acute myeloid leukemia (AML)
- Myelodysplastic syndrome (MDS)/MPN overlap syndrome
- Myeloproliferative neoplasm, blast phase (MPN-BP)
- Ability to provide informed consent electronically or through a legally authorized representative.
- Willingness to share health information, including electronic health records (EHR), laboratory values, and survey responses.
- Willingness to complete periodic patient-reported outcome (PRO) surveys and symptom tracking assessments.
Who cannot join
- Individuals under 18 years of age.
- Inability to provide informed consent, either directly or through a legally authorized representative.
- Currently enrolled in an interventional clinical trial where participation would interfere with the ability to participate in this observational registry (based on investigator or sponsor judgment).
- Any condition that, in the judgment of the study team, would make participation in the registry infeasible or unsafe.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
MPN Research Foundation
Chicago, Illinois, 60654
Stephanie Scobey, MPH, BS, RN, 847-449-5307, sscobey@mpnrf.org
David Shoultz, PhD, MBA, 7088878753, dshoultz@mpnrf.org
- Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Stephanie Scobey, MPH, BS, RN, 847-449-5307, sscobey@mpnrf.org
David Shoultz, PhD, MBA, 7088878753, dshoultz@mpnrf.org
About this study
Official title: The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), pre-fibrotic primary myelofibrosis (pre-PMF), secondary myelofibrosis, myeloproliferative neoplasm-unclassifiable (MPN-U), MPN in accelerated phase (MPN-AP), and MPN in blast phase (MPN-BP), post-MPN Acute Myeloid Leukemia (AML), and MDS/MPN overlap syndrome as defined above per WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more SCTs and/or BMTs . These conditions are characterized by abnormal blood cell production in the bone marrow and may lead to complications such as blood clots, bleeding, bone marrow fibrosis, and, in some cases, progression to acute leukemia.
The central hypothesis of the registry is that collecting and analyzing real-world, longitudinal data-including electronic health records (EHRs), laboratory values, treatments, and patient-reported outcomes (PROs)-from a diverse population of people living with MPNs will help identify patterns and predictors of disease progression, treatment response, quality of life, and long-term outcomes. These insights are intended to guide future research, inform clinical guidelines, and support improvements in patient care.
Read more
The registry is non-interventional and observational; participants do not receive investigational treatments, and all medical care continues under the supervision of their own physicians. Data collection includes EHRs, PRO surveys, patient-reported symptom and lab tracking, insurance claims, and, in the future, may include linkages with other relevant disease registries and datasets. Potential collaborations under consideration include those with the European LeukemiaNet (ELN) MPN Registry, the Mayo Clinic MPN Database, the Center for International Blood and Marrow Transplant Research (CIBMTR), the SEER Program, Harmony Alliance Foundation, and the National Cancer Database (NCDB).
The registry emphasizes the patient voice, incorporating lived experiences related to hallmark MPN symptoms such as fatigue, pruritus (itching), bone pain, night sweats, and social and emotional impacts. Participants will be followed for at least five years, with many enrolled for ten years or longer, to capture the natural history of disease and long-term outcomes. PRO surveys will be completed approximately every six months, and EHR data will be regularly reviewed to track changes in clinical status, treatment, and disease evolution.
Statistical analyses will use descriptive and inferential methods to examine clinical characteristics, symptom burden, disease trajectories, and patient-centered outcomes. Planned subgroup analyses may compare differences across diagnoses, treatment approaches, demographics, or genomic factors. Analytic plans will be finalized during the course of the study and may evolve in response to emerging scientific questions.
The registry is open to adults (18 years or older) living in the United States who have been diagnosed with any of the included MPN subtypes and are willing to share health information and complete study surveys. Individuals currently enrolled in interventional clinical trials or unable to provide informed consent may be excluded. Participation is voluntary, and participants may withdraw from the study at any time without affecting their medical care.
Privacy and data security are core priorities. Participant data will be securely stored and managed in accordance with all applicable privacy laws and research regulations. No identifiable information will be shared with external parties without appropriate authorization. Oversight is provided by a Steering Committee and a Patient Engagement Advisory Committee (PEAC), ensuring rigorous scientific, ethical, and patient-centered governance.
The registry is sponsored by the MPN Research Foundation, a nonprofit organization advancing research and patient advocacy in myeloproliferative neoplasms (MPNs). Participants can contact the registry team at any time with questions and will receive periodic updates on study findings.
This study aims to address critical gaps in understanding the real-world experiences of people with MPNs-such as symptom burden over time, risk factors for progression, and how different treatments impact patient outcomes. Findings may inform clinical trial design, support biomarker discovery, and contribute to the development of updated treatment recommendations. The registry is committed to including participants from diverse backgrounds and clinical settings to ensure findings are broadly applicable across the MPN community. Summary results will be shared through scientific publications, presentations, and other dissemination efforts to advance MPN research and care globally.
Read the detailed description
The MPN PROGRESSion Registry is a U.S.-based, prospective, observational, non-interventional study designed to track long-term clinical outcomes, treatment patterns, symptoms, quality of life, and disease progression in individuals diagnosed with myeloproliferative neoplasms (MPNs). Eligible subtypes include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), secondary MF, pre-fibrotic primary myelofibrosis (pre-PMF), myeloproliferative neoplasm-unclassifiable (MPN-U), MPN in accelerated phase (MPN-AP), MDS/MPN Overlap Syndrome, and MPN in blast phase (MPN-BP), as defined by WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplant (SCT)s and/or bone marrow transplant (BMT)s.
The registry integrates multimodal data sources-including structured electronic health record (EHR) extractions, patient-reported outcomes (PROs), medical claims, and potential future linkages with external disease registries-to generate a comprehensive, real-world dataset. This approach supports the identification of factors associated with disease trajectory, treatment response, symptom burden, and healthcare utilization, with the goal of advancing observational research, informing clinical care, and supporting regulatory science.
Participants will be enrolled over a minimum of five years, with many expected to remain in the registry for ten years or longer. An initial run-in phase aims to enroll approximately 1,500 participants to assess operational feasibility, data completeness, retention strategies, and analytic approaches. Over time, the registry will expand to include a broader, more diverse cohort capable of supporting subgroup analyses and capturing rare progression events.
The registry emphasizes patient engagement through structured PRO collection and personalized communications. PROs are collected on a tiered schedule to balance participant burden with scientific value. The MPN-SAF Total Symptom Score (TSS) and PGI-S (Patient Global Impression of Severity) are collected every three months to assess symptom burden and global health status. Every six months, participants also complete additional PROs including the EORTC QLQ-C30 (quality of life), an IRB approved Modified-PHQ-9 (mental health), and PROMIS Fatigue 8a. These PROs are supplemented by EHR refreshes, claims data, and mortality data linkages at the same six-month intervals. Participants receive automated reminders, and support is available from patient navigators. Additional engagement includes study updates, webinars, and optional non-monetary incentives.
Governance is provided by a Steering Committee composed of scientific and clinical experts and a Patient Engagement Advisory Committee (PEAC) that includes patients and caregivers from diverse backgrounds. These bodies provide ongoing oversight, ensure patient-centered governance, and advise on scientific, operational, and ethical matters. The study is approved by a central institutional review board (IRB) and complies with Good Clinical Practice (GCP), HIPAA, and all applicable regulatory standards. Participation does not influence medical care, and all treatment decisions remain solely between patients and their healthcare providers.
The registry operates under a formal quality assurance framework that includes automated and manual data validation, internal monitoring, and regular data audits. Range checks, logic rules, and reconciliation of EHR, PRO, and claims data are used to enhance data completeness and accuracy. Data elements are defined through a structured data dictionary that includes descriptions, formats, allowable ranges, and coding systems (e.g., ICD-10, SNOMED CT, LOINC, MedDRA), which is updated as needed through a documented change control process.
Personally identifiable information (PII) is separated from research data using an Honest Broker model, with encryption, access controls, and full audit trails ensuring data security and participant confidentiality. The registry complies with applicable U.S. privacy regulations, and participants may withdraw consent at any time. Data collected prior to withdrawal may continue to be used unless otherwise requested and feasible.
Statistical analyses will apply descriptive and inferential methods to examine clinical characteristics, symptom burden, treatment patterns, and progression events. Planned analyses may include comparisons across diagnostic subtypes, treatment strategies, demographics, or genetic factors. The formal statistical analysis plan (SAP) will be finalized after initial data review and is expected to evolve based on emerging scientific priorities. At this time, no independent data monitoring committee (DMC) is in place.
Planned exploratory analyses may also include comparisons or potential data harmonization with external resources such as the European LeukemiaNet (ELN) MPN Registry, the Mayo Clinic MPN Database, the Center for International Blood and Marrow Transplant Research (CIBMTR), the Surveillance, Epidemiology, and End Results (SEER) Program, the Harmony Alliance Foundation, and the National Cancer Database (NCDB), contingent on future partnerships and data-sharing agreements.
The real-world evidence (RWE) generated by this registry is intended to support a range of research goals, including understanding natural disease history, identifying risk factors, evaluating patient-reported outcomes over time, and informing the development of biomarkers and surrogate endpoints. Findings may help shape future clinical trial design, therapeutic strategies, and policy guidance. Dissemination will occur through peer-reviewed publications, conference presentations, and participant-facing summaries to ensure transparency and impact across the broader MPN community.
The registry is sponsored and administered by the MPN Research Foundation, a nonprofit organization advancing research and patient advocacy in myeloproliferative neoplasms (MPNs).
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF)
- Keywords
- Myeloproliferative Neoplasms, Polycythemia Vera, Essential Thrombocythemia, Secondary Myelofibrosis, Pre-fibrotic Primary Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Accelerated Phase, Myeloproliferative Neoplasm, Blast Phase, Chronic Myeloproliferative Disease, Hematologic Neoplasms, Bone Marrow Neoplasms, Blood Cancer, Disease Progression, Biomarker Discovery, Patient-Reported Outcomes, Electronic Health Records, Real-World Evidence, Longitudinal Study, Observational Study
- Medical subject headings
- Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis, Myeloproliferative Disorders, Blast Crisis, Hematologic Neoplasms, Bone Marrow Neoplasms, Disease Progression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| MPN Patient Cohort | Adults (18 years and older) diagnosed with a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), secondary myelofibrosis, pre-fibrotic primary myelofibrosis (pre-PMF), myeloproliferative neoplasm-unclassifiable (MPN-U), myeloproliferative neoplasm-accelerated phase (MPN-AP), myeloproliferative neoplasm-blast phase (MPN-BP), or post-MPN acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS)/MPN overlap syndrome as defined above per WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplants (SCTs) or bone marrow transplants (BMTs) enrolled in a prospective observational registry study to track clinical outcomes, disease progression, treatment patterns, patient-reported outcomes, and long-term health trajectories over time. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Disease Progression
Time from enrollment to the first documented disease progression event, defined as transformation between MPN subtypes (for example, essential thrombocythemia or polycythemia vera to myelofibrosis), development of accelerated-phase MPN (MPN-AP), progression to blast phase (MPN-BP), or meeting updated World Health Organization (WHO) or International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for disease progression. This outcome measures the rate and timing of disease evolution over time and evaluates associations with treatments, exposures, and clinical risk factors among adults diagnosed with MPNs.
Measured: Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years for participants who remain active in the registry.
Secondary outcomes (7)
Overall Survival
Time from enrollment to death from any cause among participants diagnosed with an MPN. This outcome measures overall survival patterns and examines associations between survival and treatments, risk factors, exposures, and clinical characteristics over time.
Measured: Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years for active participants.
Change in MPN-SAF Total Symptom Score (TSS)
The MPN-SAF TSS patient reported outcome (PRO) tool tracks MPN symptoms, including fatigue, pruritus, night sweats, bone pain, and early satiety.
Measured: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Event-Free Survival
Time from enrollment to first occurrence of a progression event, transformation to accelerated or blast phase, or death from any cause. This outcome provides an integrated measure of survival and disease stability among participants diagnosed with MPNs.
Measured: Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Patient Global Impression Scale - Severity (PGI-S)
The PGI-S is a PRO that captures patient-perceived overall change in health status over time.
Measured: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
EORTC QLG Core Questionnaire (QLQ-C30
The EORTC QLQ-C30 is a 30 item PRO that evaluates overall health-related quality of life, including functional status and symptom burden.
Measured: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Modified Patient Health Questionnaire (PHQ-9)
The Modified PHQ-9 is a PRO that screens for depressive symptoms commonly observed in MPN patients.
Measured: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Fatigue 8a: Assesses fatigue in MPN patients, specifically targeting the experience of fatigue and its impact on daily life.
The PROMIS Short Form v1.0 - Fatigue 8a is a PRO that assesses fatigue in MPN patients, specifically targeting the experience of fatigue and its impact on daily life.
Measured: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study start26 Sep 2025
- Primary completion8 Sep 2035 (estimated)
- Study completion8 Sep 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Polycythemia VeraStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- MPN Research Foundation
- Sponsor type
- University, hospital or other
- Collaborators
- Sobi, Inc., Karyopharm Therapeutics Inc, GlaxoSmithKline, Memorial Sloan Kettering Cancer Center
- Responsible party
- Sponsor
- Investigators
- Raajit Rampal, MD, PhD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07362225
- Sponsor's protocol ID
- MPNRF-PROG-2025-001
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 23 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The MPN PROGRESSion Registry does not plan to share individual participant data (IPD) outside the study team, sponsor, and designated governance committees. Due to the sensitive nature of patient health data and the direct-to-patient enrollment model, sharing of IPD is restricted to protect participant privacy and comply with applicable privacy laws, ethical standards, and institutional review board (IRB) requirements. Aggregate, de-identified results may be shared through scientific publications, conference presentations, and summary reports, but no participant-level data will be made publicly available.
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).
- ClinicalTrials.gov ID
- NCT07362225
- Acronym / sponsor ID
- MPNRF-PROG-2025-001
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF)
- Keywords
- Myeloproliferative Neoplasms, Polycythemia Vera, Essential Thrombocythemia, Secondary Myelofibrosis, Pre-fibrotic Primary Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Accelerated Phase
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- MPN Research FoundationUniversity, hospital or other
- Collaborators
- Sobi, Inc., Karyopharm Therapeutics Inc, GlaxoSmithKline, Memorial Sloan Kettering Cancer Center
- Study start
- 26 Sep 2025 (actual)
- Primary completion
- 8 Sep 2035 (estimated)
- Study completion
- 8 Sep 2035 (estimated)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), pre-fibrotic primary myelofibrosis (pre-PMF), secondary myelofibrosis, myeloproliferative neoplasm-unclassifiable (MPN-U), MPN in accelerated phase (MPN-AP), and MPN in blast phase (MPN-BP), post-MPN Acute Myeloid Leukemia (AML), and MDS/MPN overlap syndrome as defined above per WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more SCTs and/or BMTs . These conditions are characterized by abnormal blood cell production in the bone marrow and may lead to complications such as blood clots, bleeding, bone marrow fibrosis, and, in some cases, progression to acute leukemia.
The central hypothesis of the registry is that collecting and analyzing real-world, longitudinal data-including electronic health records (EHRs), laboratory values, treatments, and patient-reported outcomes (PROs)-from a diverse population of people living with MPNs will help identify patterns and predictors of disease progression, treatment response, quality of life, and long-term outcomes. These insights are intended to guide future research, inform clinical guidelines, and support improvements in patient care.
The registry is non-interventional and observational; participants do not receive investigational treatments, and all medical care continues under the supervision of their own physicians. Data collection includes EHRs, PRO surveys, patient-reported symptom and lab tracking, insurance claims, and, in the future, may include linkages with other relevant disease registries and datasets. Potential collaborations under consideration include those with the European LeukemiaNet (ELN) MPN Registry, the Mayo Clinic MPN Database, the Center for International Blood and Marrow Transplant Research (CIBMTR), the SEER Program, Harmony Alliance Foundation, and the National Cancer Database (NCDB).
The registry emphasizes the patient voice, incorporating lived experiences related to hallmark MPN symptoms such as fatigue, pruritus (itching), bone pain, night sweats, and social and emotional impacts. Participants will be followed for at least five years, with many enrolled for ten years or longer, to capture the natural history of disease and long-term outcomes. PRO surveys will be completed approximately every six months, and EHR data will be regularly reviewed to track changes in clinical status, treatment, and disease evolution.
Statistical analyses will use descriptive and inferential methods to examine clinical characteristics, symptom burden, disease trajectories, and patient-centered outcomes. Planned subgroup analyses may compare differences across diagnoses, treatment approaches, demographics, or genomic factors. Analytic plans will be finalized during the course of the study and may evolve in response to emerging scientific questions.
The registry is open to adults (18 years or older) living in the United States who have been diagnosed with any of the included MPN subtypes and are willing to share health information and complete study surveys. Individuals currently enrolled in interventional clinical trials or unable to provide informed consent may be excluded. Participation is voluntary, and participants may withdraw from the study at any time without affecting their medical care.
Privacy and data security are core priorities. Participant data will be securely stored and managed in accordance with all applicable privacy laws and research regulations. No identifiable information will be shared with external parties without appropriate authorization. Oversight is provided by a Steering Committee and a Patient Engagement Advisory Committee (PEAC), ensuring rigorous scientific, ethical, and patient-centered governance.
The registry is sponsored by the MPN Research Foundation, a nonprofit organization advancing research and patient advocacy in myeloproliferative neoplasms (MPNs). Participants can contact the registry team at any time with questions and will receive periodic updates on study findings.
This study aims to address critical gaps in understanding the real-world experiences of people with MPNs-such as symptom burden over time, risk factors for progression, and how different treatments impact patient outcomes. Findings may inform clinical trial design, support biomarker discovery, and contribute to the development of updated treatment recommendations. The registry is committed to including participants from diverse backgrounds and clinical settings to ensure findings are broadly applicable across the MPN community. Summary results will be shared through scientific publications, presentations, and other dissemination efforts to advance MPN research and care globally.
Detailed description
The MPN PROGRESSion Registry is a U.S.-based, prospective, observational, non-interventional study designed to track long-term clinical outcomes, treatment patterns, symptoms, quality of life, and disease progression in individuals diagnosed with myeloproliferative neoplasms (MPNs). Eligible subtypes include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), secondary MF, pre-fibrotic primary myelofibrosis (pre-PMF), myeloproliferative neoplasm-unclassifiable (MPN-U), MPN in accelerated phase (MPN-AP), MDS/MPN Overlap Syndrome, and MPN in blast phase (MPN-BP), as defined by WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplant (SCT)s and/or bone marrow transplant (BMT)s.
The registry integrates multimodal data sources-including structured electronic health record (EHR) extractions, patient-reported outcomes (PROs), medical claims, and potential future linkages with external disease registries-to generate a comprehensive, real-world dataset. This approach supports the identification of factors associated with disease trajectory, treatment response, symptom burden, and healthcare utilization, with the goal of advancing observational research, informing clinical care, and supporting regulatory science.
Participants will be enrolled over a minimum of five years, with many expected to remain in the registry for ten years or longer. An initial run-in phase aims to enroll approximately 1,500 participants to assess operational feasibility, data completeness, retention strategies, and analytic approaches. Over time, the registry will expand to include a broader, more diverse cohort capable of supporting subgroup analyses and capturing rare progression events.
The registry emphasizes patient engagement through structured PRO collection and personalized communications. PROs are collected on a tiered schedule to balance participant burden with scientific value. The MPN-SAF Total Symptom Score (TSS) and PGI-S (Patient Global Impression of Severity) are collected every three months to assess symptom burden and global health status. Every six months, participants also complete additional PROs including the EORTC QLQ-C30 (quality of life), an IRB approved Modified-PHQ-9 (mental health), and PROMIS Fatigue 8a. These PROs are supplemented by EHR refreshes, claims data, and mortality data linkages at the same six-month intervals. Participants receive automated reminders, and support is available from patient navigators. Additional engagement includes study updates, webinars, and optional non-monetary incentives.
Governance is provided by a Steering Committee composed of scientific and clinical experts and a Patient Engagement Advisory Committee (PEAC) that includes patients and caregivers from diverse backgrounds. These bodies provide ongoing oversight, ensure patient-centered governance, and advise on scientific, operational, and ethical matters. The study is approved by a central institutional review board (IRB) and complies with Good Clinical Practice (GCP), HIPAA, and all applicable regulatory standards. Participation does not influence medical care, and all treatment decisions remain solely between patients and their healthcare providers.
The registry operates under a formal quality assurance framework that includes automated and manual data validation, internal monitoring, and regular data audits. Range checks, logic rules, and reconciliation of EHR, PRO, and claims data are used to enhance data completeness and accuracy. Data elements are defined through a structured data dictionary that includes descriptions, formats, allowable ranges, and coding systems (e.g., ICD-10, SNOMED CT, LOINC, MedDRA), which is updated as needed through a documented change control process.
Personally identifiable information (PII) is separated from research data using an Honest Broker model, with encryption, access controls, and full audit trails ensuring data security and participant confidentiality. The registry complies with applicable U.S. privacy regulations, and participants may withdraw consent at any time. Data collected prior to withdrawal may continue to be used unless otherwise requested and feasible.
Statistical analyses will apply descriptive and inferential methods to examine clinical characteristics, symptom burden, treatment patterns, and progression events. Planned analyses may include comparisons across diagnostic subtypes, treatment strategies, demographics, or genetic factors. The formal statistical analysis plan (SAP) will be finalized after initial data review and is expected to evolve based on emerging scientific priorities. At this time, no independent data monitoring committee (DMC) is in place.
Planned exploratory analyses may also include comparisons or potential data harmonization with external resources such as the European LeukemiaNet (ELN) MPN Registry, the Mayo Clinic MPN Database, the Center for International Blood and Marrow Transplant Research (CIBMTR), the Surveillance, Epidemiology, and End Results (SEER) Program, the Harmony Alliance Foundation, and the National Cancer Database (NCDB), contingent on future partnerships and data-sharing agreements.
The real-world evidence (RWE) generated by this registry is intended to support a range of research goals, including understanding natural disease history, identifying risk factors, evaluating patient-reported outcomes over time, and informing the development of biomarkers and surrogate endpoints. Findings may help shape future clinical trial design, therapeutic strategies, and policy guidance. Dissemination will occur through peer-reviewed publications, conference presentations, and participant-facing summaries to ensure transparency and impact across the broader MPN community.
The registry is sponsored and administered by the MPN Research Foundation, a nonprofit organization advancing research and patient advocacy in myeloproliferative neoplasms (MPNs).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MPN Patient Cohort | – | –Adults (18 years and older) diagnosed with a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), secondary myelofibrosis, pre-fibrotic primary myelofibrosis (pre-PMF), myeloproliferative neoplasm-unclassifiable (MPN-U), myeloproliferative neoplasm-accelerated phase (MPN-AP), myeloproliferative neoplasm-blast phase (MPN-BP), or post-MPN acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS)/MPN overlap syndrome as defined above per WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplants (SCTs) or bone marrow transplants (BMTs) enrolled in a prospective observational registry study to track clinical outcomes, disease progression, treatment patterns, patient-reported outcomes, and long-term health trajectories over time. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults (18 years and older) diagnosed with a myeloproliferative neoplasm (MPN), including polycythemia vera, essential thrombocythemia, primary myelofibrosis, secondary myelofibrosis, pre-fibrotic primary myelofibrosis, MPN-unclassifiable, MPN-accelerated phase, or MPN-blast phase, post-MPN AML, or MDS/MPN overlap syndrome (including patients originally diagnosed with one of these conditions but who have received one or more SCTs or BMTs) residing in the United States. Participants are enrolled exclusively through direct-to-patient outreach using online recruitment, social media, digital advertising, and patient advocacy networks. All participants must provide electronic informed consent, have accessible electronic health record (EHR) data, and be willing to complete digital patient-reported outcome surveys. The study aims to capture a diverse national cohort for real-world, longitudinal research on disease progression, treatment patterns, and outcomes .
Key inclusion criteria (16 listed)
- Adults aged 18 years or older at the time of enrollment.
- Confirmed diagnosis of a myeloproliferative neoplasm (MPN), including one or more of the following subtypes, according to WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplants (SCTs) or bone marrow transplants (BMTs):
- Polycythemia vera (PV)
- Essential thrombocythemia (ET)
- Primary myelofibrosis (PMF)
Key exclusion criteria (4 listed)
- Individuals under 18 years of age.
- Inability to provide informed consent, either directly or through a legally authorized representative.
- Currently enrolled in an interventional clinical trial where participation would interfere with the ability to participate in this observational registry (based on investigator or sponsor judgment).
- Any condition that, in the judgment of the study team, would make participation in the registry infeasible or unsafe.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Time to Disease Progression
Time frame: Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years for participants who remain active in the registry.
Time from enrollment to the first documented disease progression event, defined as transformation between MPN subtypes (for example, essential thrombocythemia or polycythemia vera to myelofibrosis), development of accelerated-phase MPN (MPN-AP), progression to blast phase (MPN-BP), or meeting updated World Health Organization (WHO) or International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for disease progression. This outcome measures the rate and timing of disease evolution over time and evaluates associations with treatments, exposures, and clinical risk factors among adults diagnosed with MPNs.
7 secondary outcomes
Overall Survival
Time frame: Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years for active participants.
Change in MPN-SAF Total Symptom Score (TSS)
Time frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Event-Free Survival
Time frame: Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Patient Global Impression Scale - Severity (PGI-S)
Time frame: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
EORTC QLG Core Questionnaire (QLQ-C30
Time frame: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Modified Patient Health Questionnaire (PHQ-9)
Time frame: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Fatigue 8a: Assesses fatigue in MPN patients, specifically targeting the experience of fatigue and its impact on daily life.
Time frame: Time Frame: Assessed every 3-6 months over a minimum of 5 years per participant, with extended follow-up beyond 10 years where applicable.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2026.
- MPN Research Foundation MPN PROGRESSion Registry WebpageLink provided by the sponsor.
- Individual participant dataSharing planned: No. The MPN PROGRESSion Registry does not plan to share individual participant data (IPD) outside the study team, sponsor, and designated governance committees. Due to the sensitive nature of patient health data and the direct-to-patient enrollment model, sharing of IPD is restricted to protect participant privacy and comply with applicable privacy laws, ethical standards, and institutional review board (IRB) requirements. Aggregate, de-identified results may be shared through scientific publications, conference presentations, and summary reports, but no participant-level data will be made publicly available.
Related trials for Polycythemia Vera
RecruitingPhase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
RecruitingPhase 2/3
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Polycythemia Vera
RecruitingPhase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
RecruitingPhase 2
A Study of Ropeg-Interferon in People With Polycythemia Vera
Polycythemia Vera (PV), JAK2 Mutation
Active, not recruitingPhase 2
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Polycythemia Vera (PV)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Raajit Rampal, MD, PhD principal investigator
Memorial Sloan Kettering Cancer Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Polycythemia Vera and ET (Essential Thrombocythemia), run by MPN Research Foundation at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stephanie Scobey, MPN, BS, RN (847-449-5307, sscobey@mpnrf.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Disease Progression (time frame: Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years for participants who remain active in the registry.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2026.